Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients

Modern Rheumatology

Volumn 23, Issue 5, 2013, Pages 904-912

  Takahashi, Nobunori ^a   Kojima, Toshihisa ^a   Terabe, Kenya ^a   Kaneko, Atsushi ^b   Kida, Daihei ^b   Hirano, Yuji ^c   Fujibayashi, Takayoshi ^d   Yabe, Yuichiro ^e   Takagi, Hideki ^f   Oguchi, Takeshi ^g   Miyake, Hiroyuki ^h   Kato, Takefumi ⁱ   Fukaya, Naoki ^j   Ishikawa, Hisato ^b   Hayashi, Masatoshi ^k   Tsuboi, Seiji ^l   Kato, Daizo ^a   Funahashi, Koji ^a   Matsubara, Hiroyuki ^a   Hattori, Yosuke ^a   Hanabayashi, Masahiro ^a   Hirabara, Shinya ^a   Yoshioka, Yutaka ^a   Ishiguro, Naoki ^a   more..

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^d Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

^e TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^f Nagoya Kyoritsu Hospital   (Japan)

^g ANJO KOSEI HOSPITAL   (Japan)

^h Ichinomiya Municipal Hospital   (Japan)

ⁱ Kato Orthopedic Clinic   (Japan)

^j Toyota Kai Medical Corporation Kariya Toyota General Hospital   (Japan)

^k NAGANO RED CROSS HOSPITAL   (Japan)

^l Shizuoka Kosei Hospital   (Japan)

more..

Author keywords

Abatacept; Concomitant methotrexate; Japanese patients; Prior biologics; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TOCILIZUMAB;

ADULT; AGED; APPENDICITIS; ARTICLE; BRONCHOPNEUMONIA; CELLULITIS; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; INTERSTITIAL PNEUMONIA; LIVER FUNCTION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; PURPURA; RESPIRATORY TRACT INFLAMMATION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCONJUGATES; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84885182194     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0760-4     Document Type: Article

References (24)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358(9285):903- 11.
2. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344(12):907-16.
3. Goronzy JJ, Weyand CM. T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol. 2004;16(3):212-7.
4. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-58.
5. Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR. Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol. 2000;165(9):5041-7.
6. Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol. 2002;13(2):559-75.
7. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis. 2009;68(12):1870-7.
8. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144(12):865-76.
9. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67(8):1096-103.
10. Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis. 2011;70(10):1826-30.
11. Schiff M, Pritchard C, Huffstutter JE, Rodriguez-Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68(11):1708-14.
12. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-23.
13. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011;70(7):1216-22.
14. Danoy P, Wei M, Johanna H, Jiang L, He D, Sun L, et al. Association of variants in MMEL1 and CTLA4 with rheumatoid arthritis in the Han Chinese population. Ann Rheum Dis. 2011;70(10):1793-7.
15. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol. 2012;22:370-5.
16. Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, et al. Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) Study. Mod Rheumatol. 2012;22:339-45.
17. ®) for the treatment of rheumatoid arthritis. Nihon Yakurigaku Zasshi. 2011;137(2):87-94.
18. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-81.
19. Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. Continuation of methotrexate resulted in better clinical and radiographic outcomes than discontinuation upon starting etanercept in patients with rheumatoid arthritis: 52-week results from the JESMR study. J Rheumatol. 2011;38(8):1585-92.
20. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26-37.
21. Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E, Hirata S, Kurasawa T, et al. Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol. 2012;22:327-38.
22. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-29.
23. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients - REACTION 52-week study. Rheumatology (Oxford). 2011;50(10):1908-15.
24. Tanaka Y. Abatacept demonstrated long-term safety and efficacy in active RA patients who showed inadequate response to methotrexate: an analysis of the Japanese phase III open-label, long-term extension trial. Presented at the 14th Asian Pacific League of Associations for Rheumatology (APLAR) Congress. Hong Kong, 2010. p. FP6-1.